NO20060123L - Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi - Google Patents
Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapiInfo
- Publication number
- NO20060123L NO20060123L NO20060123A NO20060123A NO20060123L NO 20060123 L NO20060123 L NO 20060123L NO 20060123 A NO20060123 A NO 20060123A NO 20060123 A NO20060123 A NO 20060123A NO 20060123 L NO20060123 L NO 20060123L
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- disorder
- steroid hormone
- uterine
- type
- Prior art date
Links
- UELJJSQADCDBMU-UHFFFAOYSA-N 3h-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical class S1C2=CC=CC=C2C2=C1N=CNC2=O UELJJSQADCDBMU-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 230000001419 dependent effect Effects 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 239000003270 steroid hormone Substances 0.000 abstract 3
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 2
- 206010000496 acne Diseases 0.000 abstract 2
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 abstract 1
- 208000005641 Adenomyosis Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010058314 Dysplasia Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010039792 Seborrhoea Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 201000006828 endometrial hyperplasia Diseases 0.000 abstract 1
- 201000009274 endometriosis of uterus Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 208000007106 menorrhagia Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 201000007094 prostatitis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
- 230000037303 wrinkles Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Joining Of Glass To Other Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47704703P | 2003-06-10 | 2003-06-10 | |
| PCT/EP2004/006230 WO2005032527A2 (en) | 2003-06-10 | 2004-06-09 | Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060123L true NO20060123L (no) | 2006-03-09 |
Family
ID=34421462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060123A NO20060123L (no) | 2003-06-10 | 2006-01-09 | Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7465739B2 (enExample) |
| EP (1) | EP1635839B1 (enExample) |
| JP (1) | JP4605800B2 (enExample) |
| KR (1) | KR20060054189A (enExample) |
| CN (1) | CN1791412A (enExample) |
| AR (1) | AR044650A1 (enExample) |
| AT (1) | ATE479437T1 (enExample) |
| AU (1) | AU2004277311B8 (enExample) |
| BR (1) | BRPI0411295A (enExample) |
| CA (1) | CA2527617A1 (enExample) |
| DE (1) | DE602004028934D1 (enExample) |
| DK (1) | DK1635839T3 (enExample) |
| ES (2) | ES2352552T3 (enExample) |
| IL (1) | IL172316A0 (enExample) |
| MX (1) | MXPA05012745A (enExample) |
| NO (1) | NO20060123L (enExample) |
| PL (1) | PL1635839T3 (enExample) |
| PT (1) | PT1635839E (enExample) |
| RU (1) | RU2412190C2 (enExample) |
| SA (1) | SA04250159B1 (enExample) |
| SI (1) | SI1635839T1 (enExample) |
| TW (1) | TWI349551B (enExample) |
| WO (1) | WO2005032527A2 (enExample) |
| ZA (1) | ZA200508296B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7524853B2 (en) | 2003-06-10 | 2009-04-28 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| WO2005108376A1 (en) * | 2004-05-06 | 2005-11-17 | Smithkline Beecham Corporation | Calcilytic compounds |
| WO2006044826A2 (en) * | 2004-10-20 | 2006-04-27 | Compass Pharmaceuticals Llc | Thiophens and their use as anti-tumor agents |
| BRPI0419229A (pt) * | 2004-12-13 | 2007-12-18 | Solvay Pharm Gmbh | derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica |
| FR2904000A1 (fr) * | 2006-07-19 | 2008-01-25 | Galderma Res & Dev S N C Snc | Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee |
| FR2904318B1 (fr) * | 2006-07-27 | 2011-02-25 | Scras | Derives de pyrimidinone et leur utilisation comme medicament |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| WO2009001214A2 (en) * | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
| DE102007040243A1 (de) * | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| EP2381775A4 (en) * | 2008-12-23 | 2012-08-15 | Harvard College | INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE |
| EP2609089A1 (en) | 2010-08-27 | 2013-07-03 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| WO2012119605A1 (en) * | 2011-03-10 | 2012-09-13 | Akar Yahya Ahmed Abdellhafeez Salem | New disperse dye with potent anticancer activity |
| TW201520219A (zh) * | 2013-03-12 | 2015-06-01 | Lilly Co Eli | 咪唑並吡啶化合物 |
| EP2968276A4 (en) | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
| AR096728A1 (es) | 2013-06-25 | 2016-01-27 | Forendo Pharma Ltd | Derivados de estratrieno-tiazol terapéuticamente activos |
| AR096729A1 (es) | 2013-06-25 | 2016-01-27 | Forendo Pharma Ltd | Derivados terapéuticamente activos de estratien-tiazol |
| JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| EP3089969A2 (en) | 2014-01-03 | 2016-11-09 | Elexopharm GmbH | Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2 |
| WO2015114663A1 (en) | 2014-01-30 | 2015-08-06 | Council Of Scientific & Industrial Research | Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties |
| GB201419102D0 (en) * | 2014-10-27 | 2014-12-10 | Imp Innovations Ltd | Novel compounds |
| WO2016102775A1 (en) | 2014-12-23 | 2016-06-30 | Forendo Pharma Ltd | PRODRUGS OF 17β-HSD1 -INHIBITORS |
| JP6523461B2 (ja) | 2014-12-23 | 2019-06-05 | フォレンド ファーマ リミテッド | １７β−ＨＳＤ１−阻害剤のプロドラッグ |
| CA3003930A1 (en) * | 2015-11-04 | 2017-05-11 | Simon Fraser University | Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor |
| DK3634975T3 (da) | 2017-06-08 | 2024-05-27 | Organon R&D Finland Ltd | 17-oximer af 15.beta.-[3-propanamido]-substituerede estra-1,3,5(10)-trien-17-oner til anvendelse i inhibition af 17.beta.-hydroxysteroid-dehydrogenaser |
| CN109503572B (zh) * | 2017-09-15 | 2021-10-08 | 上海交通大学 | 一种合成吲哚喹啉类化合物的方法 |
| CA3122049C (en) | 2018-12-05 | 2023-10-17 | Forendo Pharma Ltd | Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 |
| AU2023260728A1 (en) * | 2022-04-28 | 2024-10-10 | Enanta Pharmaceuticals, Inc. | Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors |
| US20250154163A1 (en) * | 2023-10-26 | 2025-05-15 | Enanta Pharmaceuticals, Inc. | Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4742271B1 (enExample) * | 1968-06-20 | 1972-10-25 | ||
| US3775027A (en) | 1971-10-01 | 1973-11-27 | Gray Manuf Co Inc | Two-speed pump |
| JPS62132884A (ja) | 1985-12-05 | 1987-06-16 | Mitsubishi Chem Ind Ltd | ２−ベンジルチエノ〔２，３−ｄ〕ピリミジン−４（３Ｈ）−オン誘導体 |
| WO1989008113A1 (en) | 1988-03-02 | 1989-09-08 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL APPLICATION THEREOF |
| US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| JP3783810B2 (ja) | 1997-01-14 | 2006-06-07 | 第一製薬株式会社 | 新規ベンゾフラノン誘導体及びその製造方法 |
| JPH10273467A (ja) | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
| AU9001698A (en) | 1997-09-11 | 1999-03-29 | Snow Brand Milk Products Co., Ltd. | Remedies for hormone-dependent diseases |
| TR200002784T2 (tr) | 1998-03-11 | 2000-12-21 | Endorecherche, Inc | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar |
| US6291505B1 (en) | 1998-08-07 | 2001-09-18 | Chiron Corporation | Estrogen receptor modulators |
| GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
| AU2001296961A1 (en) | 2000-09-29 | 2002-04-08 | Bayer Pharmaceuticals Corporation | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors |
| WO2003017974A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method |
| ES2276950T3 (es) | 2001-09-06 | 2007-07-01 | Schering Corporation | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos. |
| US6750248B2 (en) | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
-
2004
- 2004-06-07 US US10/861,907 patent/US7465739B2/en not_active Expired - Fee Related
- 2004-06-08 AR ARP040101983A patent/AR044650A1/es not_active Application Discontinuation
- 2004-06-08 TW TW093116411A patent/TWI349551B/zh not_active IP Right Cessation
- 2004-06-09 BR BRPI0411295-4A patent/BRPI0411295A/pt not_active IP Right Cessation
- 2004-06-09 WO PCT/EP2004/006230 patent/WO2005032527A2/en not_active Ceased
- 2004-06-09 CA CA002527617A patent/CA2527617A1/en not_active Abandoned
- 2004-06-09 EP EP04803089A patent/EP1635839B1/en not_active Expired - Lifetime
- 2004-06-09 ZA ZA200508296A patent/ZA200508296B/xx unknown
- 2004-06-09 RU RU2006100033/04A patent/RU2412190C2/ru not_active IP Right Cessation
- 2004-06-09 DE DE602004028934T patent/DE602004028934D1/de not_active Expired - Lifetime
- 2004-06-09 AU AU2004277311A patent/AU2004277311B8/en not_active Ceased
- 2004-06-09 AT AT04803089T patent/ATE479437T1/de active
- 2004-06-09 PL PL04803089T patent/PL1635839T3/pl unknown
- 2004-06-09 JP JP2006515869A patent/JP4605800B2/ja not_active Expired - Fee Related
- 2004-06-09 KR KR1020057022958A patent/KR20060054189A/ko not_active Abandoned
- 2004-06-09 MX MXPA05012745A patent/MXPA05012745A/es active IP Right Grant
- 2004-06-09 SI SI200431535T patent/SI1635839T1/sl unknown
- 2004-06-09 DK DK04803089.4T patent/DK1635839T3/da active
- 2004-06-09 PT PT04803089T patent/PT1635839E/pt unknown
- 2004-06-09 ES ES04803089T patent/ES2352552T3/es not_active Expired - Lifetime
- 2004-06-09 CN CNA200480013515XA patent/CN1791412A/zh active Pending
- 2004-06-12 SA SA4250159A patent/SA04250159B1/ar unknown
- 2004-11-03 ES ES04805369T patent/ES2352554T3/es not_active Expired - Lifetime
-
2005
- 2005-12-01 IL IL172316A patent/IL172316A0/en unknown
-
2006
- 2006-01-09 NO NO20060123A patent/NO20060123L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US7465739B2 (en) | 2008-12-16 |
| RU2006100033A (ru) | 2007-07-20 |
| MXPA05012745A (es) | 2006-05-17 |
| TW200509937A (en) | 2005-03-16 |
| AU2004277311B8 (en) | 2010-05-27 |
| WO2005032527A3 (en) | 2005-08-04 |
| AU2004277311A1 (en) | 2005-04-14 |
| TWI349551B (en) | 2011-10-01 |
| WO2005032527B1 (en) | 2005-09-22 |
| ZA200508296B (en) | 2007-01-31 |
| AR044650A1 (es) | 2005-09-21 |
| EP1635839B1 (en) | 2010-09-01 |
| AU2004277311B2 (en) | 2010-04-29 |
| KR20060054189A (ko) | 2006-05-22 |
| PT1635839E (pt) | 2010-10-12 |
| SA04250159B1 (ar) | 2008-06-21 |
| CN1791412A (zh) | 2006-06-21 |
| ATE479437T1 (de) | 2010-09-15 |
| BRPI0411295A (pt) | 2006-08-01 |
| EP1635839A2 (en) | 2006-03-22 |
| ES2352552T3 (es) | 2011-02-21 |
| DK1635839T3 (da) | 2011-01-03 |
| PL1635839T3 (pl) | 2011-02-28 |
| RU2412190C2 (ru) | 2011-02-20 |
| DE602004028934D1 (de) | 2010-10-14 |
| IL172316A0 (en) | 2011-08-01 |
| JP4605800B2 (ja) | 2011-01-05 |
| US20050038053A1 (en) | 2005-02-17 |
| CA2527617A1 (en) | 2005-04-14 |
| JP2006527226A (ja) | 2006-11-30 |
| SI1635839T1 (sl) | 2010-12-31 |
| ES2352554T3 (es) | 2011-02-21 |
| WO2005032527A2 (en) | 2005-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060123L (no) | Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi | |
| NO20045461L (no) | Nye pyridazin 3-(2H)-on derivater som PDE4-inhibitorer | |
| Messinger et al. | New inhibitors of 17β-hydroxysteroid dehydrogenase type 1 | |
| JP4612628B2 (ja) | １７−β−ヒドロキシステロイドデヒドロゲナーゼのインヒビターとしてのチオフェンピリミジノン | |
| DE69113795D1 (de) | Steroid 5-alpha-reduktase. | |
| PA8569501A1 (es) | Compuestos utiles en terapia | |
| TW200516079A (en) | Isethionate salt of a selective CDK4 inhibitor | |
| DE60309667D1 (de) | Biphenylderivate und ihre verwendung als antiandrogene | |
| AU7950000A (en) | Imidazol-4-ylmethanols use as inhibitors of steroid c17-20 lyase | |
| BRPI0708779A2 (pt) | derivados de pirrolopirimidina utilizados como inibidores de hsp90 | |
| DE60307856D1 (de) | Antitumorverbindung und ihre therapeutischen verwendungen | |
| TW200505912A (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| Zhao et al. | Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors | |
| Jo et al. | Chromenylchalcones with inhibitory effects on monoamine oxidase B | |
| Huang et al. | Structure-guided development of purine amide, hydroxamate, and amidoxime for the inhibition of non-small cell lung cancer | |
| Roy-Burman et al. | Androgens and prostate cancer: are the descriptors valid? | |
| Cui et al. | Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors | |
| Muftuoglu et al. | Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19) | |
| Miller et al. | Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach | |
| K Morrow et al. | Recent development of anticancer therapeutics targeting Akt | |
| CY1110589T1 (el) | ΠΑΡΑΓΩΓΑ ΤΗΣ ΘΕΙΕΝΟ(2,3-b)ΠΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΤΗΣ ΟΡΜΟΝΗΣ ΑΠΕΛΕΥΘΕΡΩΣΕΩΣ ΓΟΝΑΔΟΤΡΟΠΟΥ ΟΡΜΟΝΗΣ | |
| Mastracchio et al. | Investigation of biaryl heterocycles as inhibitors of Wee1 kinase | |
| Poirier et al. | A multidetachable sulfamate linker successfully used in a solid-phase strategy to generate libraries of sulfamate and phenol derivatives | |
| Ying et al. | Intracellular effects of prodrug-like wortmannin probes | |
| AU2003216084A1 (en) | Methods for therapeutic treatment of benign prostatic hypertrophy (bph) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |